Roivant Sciences (ROIV)

• Market cap: $8.13B
• 1 day: -0.36%
• 5 days: 2.10%
• 1 month: -6.92%
• 3 months: -5.34%
• 6 months: 3.91%
• Year to date: -7.53%
• 1 year: 7.40%
• 5 years: 19.47%
• 10 years: 19.47%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees: 908

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

71% more repeat investments, than reductions

Existing positions increased: 120 | Existing positions reduced: 70

8% more capital invested

Capital invested by funds: $6.09B [Q2] → $6.55B (+$457M) [Q3]

2% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 53

1.27% less ownership

Funds ownership: 77.99% [Q2] → 76.72% (-1.27%) [Q3]

1% less funds holding

Funds holding: 293 [Q2] → 289 (-4) [Q3]

11% less funds holding in top 10

Funds holding in top 10: 19 [Q2] → 17 (-2) [Q3]

47% less call options, than puts

Call options by funds: $17.6M | Put options by funds: $33.3M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $18 61% upside
• Avg. target: $18 61% upside
• High target: $18 61% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 35% 1-year accuracy 62 / 175 met price target

61% upside $18

Buy Reiterated

13 Nov 2024